ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability

MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...

Merck Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients With Platinum-Resistant Recurren…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-B96 trial, ...
U.S. News & World Report

BDT & MSD's Alliance Laundry Targets $4.3 Billion Valuation in US IPO

(Reuters) -Alliance Laundry is targeting a valuation of up to $4.34 billion in its U.S. initial public offering, the commercial laundry equipment maker said on Monday, as the frenzy around first-time ...
The Joplin Globe

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA ® (pembrolizumab), Merck’s ...

Efficient MSD volleyball advances in playoffs with win over Perry Hall

During the second set of Tuesday’s volleyball match, Maryland School for the Deaf outside hitter Maliyah Coleman dove to the floor and rolled out of Emma Le’s path so the Orioles setter could move ...